Skip to main content

Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ: CRNX · IEX Real-Time Price · USD
24.40 -3.08 (-11.21%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap1.16B
Revenue (ttm)n/a
Net Income (ttm)-98.49M
Shares Out47.50M
EPS (ttm)-2.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume184,756
Open27.50
Previous Close27.48
Day's Range23.65 - 27.95
52-Week Range12.60 - 28.78
Beta1.37
AnalystsBuy
Price Target38.80 (+59.0%)
Earnings DateNov 5, 2021

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developin...

IndustryBiotechnology
IPO DateJul 18, 2018
CEOR. Scott Struthers
Employees93
Stock ExchangeNASDAQ
Ticker SymbolCRNX
Full Company Profile

Financial Performance

In 2020, CRNX's revenue was $71,000, a decrease of -94.05% compared to the previous year's $1.19 million. Losses were -$73.81 million, 46.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 38.80, which is an increase of 59.02% from the latest price.

Price Target
$38.80
(59.02% upside)
Analyst Consensus: Buy

News

Does Crinetics Pharmaceuticals, Inc. (CRNX) Have the Potential to Rally 35% as Wall Street Analysts Expect?

The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

1 week ago - Zacks Investment Research

What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for "Trend Investing"

Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

2 weeks ago - Zacks Investment Research

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Soc...

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

2 weeks ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

– Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts –

3 weeks ago - GlobeNewsWire

Wall Street Analysts Believe Crinetics Pharmaceuticals, Inc. (CRNX) Could Rally 45%: Here's is How to Trade

The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

3 weeks ago - Zacks Investment Research

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwrite...

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

1 month ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

1 month ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

1 month ago - GlobeNewsWire

Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) spun out a new company, Radionetics, focused solely on a burgeoning field of radiopharmaceuticals. Radiopharmaceuticals are a class of drugs that contain rad...

1 month ago - Benzinga

Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted ...

Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier

1 month ago - GlobeNewsWire

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for B...

- Late-breaking Poster Presentation on Sunday, October 3, 2021

2 months ago - GlobeNewsWire

Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-de...

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms

2 months ago - GlobeNewsWire

Crinetics Pharmaceuticals to Participate in September Investor Conferences

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel ther...

2 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov...

2 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

– Commenced dosing in Phase 3 PATHFNDR-1 study –

3 months ago - GlobeNewsWire

Crinetics Pharmaceuticals' Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Depe...

CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts

3 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

3 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine f...

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -

4 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel...

5 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021

6 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and F...

Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET

8 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI Programs Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI P...

8 months ago - GlobeNewsWire